

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

N : cells not stimulated with bFGF

S : cells stimulated with bFGF





Fig.1

N S : cells not stimulated with bFGF

S : cells stimulated with bFGF



Development with anti-phosphotyrosine antibody

Fig.2

LOT 1 LOT 2 LOT 3 LOT 4




Fig. 3



Figure 4A

Subconjunctival injections
of antisense oligonucleotides
(60 μ M)




Figure 4B

Subconjunctival injections
of sense oligonucleotides
(60 μ M)




Figure 4C

Topical applications of
antisense oligonucleotide
(200 μ M)




Figure 4D

Topical applications of sense
oligonucleotide (200 μ M)




Figure 4E

No treatment




Figure 4F

Subconjunctival injections
of PBS

ANTISENSE OLIGONUCLEOTIDES CAPABLE OF...

Inventor: Salman Al-Mahmood

EMC: EL 978573814 US

Sheet 5 of 5

Docket No. 1414-03

Piper Rudnick LLP (215) 656-3381



Figure 5A



Figure 5F




Figure 5B



Figure 5G



Figure 5C



Figure 5H




Figure 5D



Figure 5I



Figure 5E



Figure 5J

- Fig. 5A - Day 4 AS [antisense] 60
- Fig. 5B - Day 4 AS [antisense] 200
- Fig. 5C - Day 4 S [sense] 200
- Fig. 5D - Day 4 PBS
- Fig. 5E - Day 4 No treatment
- Fig. 5F - Day 9 AS [antisense] 60
- Fig. 5G - Day 9 AS [antisense] 200
- Fig. 5H - Day 9 S [sense] 200
- Fig. 5I - Day 9 PBS
- Fig. 5J - Day 9 No treatment